ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $11,218,000 | +35.8% | 65,185 | -1.0% | 0.02% | +37.5% |
| Q2 2021 | $8,263,000 | -8.2% | 65,843 | -0.8% | 0.02% | -11.1% |
| Q1 2021 | $9,003,000 | +3.1% | 66,386 | -2.7% | 0.02% | 0.0% |
| Q4 2020 | $8,729,000 | +38.6% | 68,226 | +21.9% | 0.02% | +28.6% |
| Q3 2020 | $6,296,000 | +21.4% | 55,948 | +2.7% | 0.01% | +7.7% |
| Q2 2020 | $5,188,000 | +140.9% | 54,458 | +127.2% | 0.01% | +85.7% |
| Q1 2020 | $2,154,000 | +69.5% | 23,964 | 0.0% | 0.01% | +133.3% |
| Q4 2019 | $1,271,000 | +35.2% | 23,964 | +0.8% | 0.00% | +50.0% |
| Q3 2019 | $940,000 | -3.8% | 23,784 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $977,000 | -4.0% | 23,784 | +8.8% | 0.00% | 0.0% |
| Q1 2019 | $1,018,000 | +6.8% | 21,864 | -0.1% | 0.00% | 0.0% |
| Q4 2018 | $953,000 | -23.5% | 21,884 | +0.6% | 0.00% | 0.0% |
| Q3 2018 | $1,245,000 | +18.0% | 21,751 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,055,000 | +42.0% | 21,751 | +14.4% | 0.00% | +50.0% |
| Q1 2018 | $743,000 | -7.0% | 19,011 | +0.9% | 0.00% | 0.0% |
| Q4 2017 | $799,000 | +17.7% | 18,838 | +3.5% | 0.00% | 0.0% |
| Q3 2017 | $679,000 | +22.8% | 18,198 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $553,000 | +14.7% | 18,198 | 0.0% | 0.00% | +100.0% |
| Q1 2017 | $482,000 | +3.9% | 18,198 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $464,000 | -29.6% | 18,198 | 0.0% | 0.00% | -50.0% |
| Q3 2016 | $659,000 | +7.3% | 18,198 | +0.7% | 0.00% | 0.0% |
| Q2 2016 | $614,000 | +30.1% | 18,078 | +1.0% | 0.00% | 0.0% |
| Q1 2016 | $472,000 | -45.9% | 17,893 | 0.0% | 0.00% | -33.3% |
| Q4 2015 | $872,000 | +97.3% | 17,893 | +0.8% | 0.00% | +50.0% |
| Q3 2015 | $442,000 | -21.4% | 17,753 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $562,000 | -1.1% | 17,753 | +18.9% | 0.00% | 0.0% |
| Q1 2015 | $568,000 | -1.6% | 14,931 | +0.8% | 0.00% | 0.0% |
| Q4 2014 | $577,000 | +28.8% | 14,811 | 0.0% | 0.00% | +100.0% |
| Q3 2014 | $448,000 | -10.9% | 14,811 | 0.0% | 0.00% | -50.0% |
| Q2 2014 | $503,000 | – | 14,811 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |